Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
3 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-01-31
Study Completion Date
2017-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to determine whether vitamin K supplementation will improve anticoagulation control in patients on hemodialysis taking warfarin for atrial fibrillation. Patients who participate will receive vitamin K1 three times a week on dialysis days for a period of four months. INR levels collected during this period will be compared to the four month period prior to receiving the vitamin K1 to determine if vitamin K improves the standard deviation of INRs and time in therapeutic range.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients
NCT03311321
Cardiovascular Diseases
Chronic Kidney Disease Stage 3
Chronic Kidney Disease Stage 4
+3 more
UNKNOWN
NA
Underlying Causes of Low Vitamin K Status in Hemodialysis Patients
NCT03493087
Renal Insufficiency, Chronic
COMPLETED
NA
Incorporation of Vitamin K Into Uremic Lipoproteins
NCT05360342
Vitamin K Deficiency
COMPLETED
NA
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
NCT02976246
Vitamin K Supplementation
Endstage Renal Disease
Cardiovascular Disease
+1 more
COMPLETED
PHASE4
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
NCT02278692
Calciphylaxis
Calcific Uremic Arteriolopathy
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients on hemodialysis with atrial fibrillation are at increased risk of stroke. These patients often take warfarin to reduce this risk. Warfarin is a drug that is used to prevent clots in the bloodstream. The dose of warfarin varies from person to person, and its effect is measured using a blood test called the international normalized ratio (INR). In most patients with atrial fibrillation the goal is to keep the INR between 2 and 3. Patients on hemodialysis often have unstable INR levels. Vitamin K supplementation has been shown to improve INR control in patients on warfarin but has not yet been studied in hemodialysis patients.
In this study, patients on hemodialysis receiving warfarin for atrial fibrillation will receive vitamin K 400 mcg orally three times a week on dialysis days for 4 months. INR levels in the four months before and the four months while receiving vitamin K will be reviewed.
The primary end point will look at INR stability and be measured by calculating the standard deviation of INR values before and after receiving vitamin K. The goal of this study is to determine whether vitamin K supplementation improves INR control in patients on hemodialysis taking warfarin for atrial fibrillation.
In this study, patients on hemodialysis receiving warfarin for atrial fibrillation will receive vitamin K 400 mcg orally three times a week on dialysis days for 4 months. INR levels in the four months before and the four months while receiving vitamin K will be reviewed.
The primary end point will look at INR stability and be measured by calculating the standard deviation of INR values before and after receiving vitamin K. The goal of this study is to determine whether vitamin K supplementation improves INR control in patients on hemodialysis taking warfarin for atrial fibrillation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
End Stage Renal Failure on Dialysis
Atrial Fibrillation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin K1
Vitamin K1 400 mcg orally three times a week on dialysis days for four months
Group Type
OTHER
vitamin K1
Intervention Type
DRUG
Vitamin K1 400 mcg orally three times a week on dialysis days for four months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
vitamin K1
Vitamin K1 400 mcg orally three times a week on dialysis days for four months
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
phytonadione
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* greater than 18 years of age
* Receiving in-house hemodialysis for at least 6 months
* Previously diagnosed with atrial fibrillation
* On warfarin for at least 6 months with a target INR of 2-3
* Receiving in-house hemodialysis for at least 6 months
* Previously diagnosed with atrial fibrillation
* On warfarin for at least 6 months with a target INR of 2-3
Exclusion Criteria
* are unable to provide informed consent
* have a mechanical heart valve
* are receiving supplements containing vitamin K
* have a known hypersensitivity to vitamin K
* have a mechanical heart valve
* are receiving supplements containing vitamin K
* have a known hypersensitivity to vitamin K
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marisa Battistella
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network
Toronto, Ontario, Canada
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Canada
References
Explore related publications, articles, or registry entries linked to this study.
Reinecke H, Engelbertz C, Schabitz WR. Preventing stroke in patients with chronic kidney disease and atrial fibrillation: benefit and risks of old and new oral anticoagulants. Stroke. 2013 Oct;44(10):2935-41. doi: 10.1161/STROKEAHA.113.001701. Epub 2013 Sep 5. No abstract available.
Reference Type
BACKGROUND
Sood MM, Komenda P, Sood AR, Rigatto C, Bueti J. The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? Chest. 2009 Oct;136(4):1128-1133. doi: 10.1378/chest.09-0730.
Reference Type
BACKGROUND
Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014 Mar 18;129(11):1196-203. doi: 10.1161/CIRCULATIONAHA.113.004777. Epub 2014 Jan 22.
Reference Type
BACKGROUND
Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011 Mar 22;57(12):1339-48. doi: 10.1016/j.jacc.2010.12.013.
Reference Type
BACKGROUND
Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, Mitchell LB, Verma A, Nattel S; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012 Mar-Apr;28(2):125-36. doi: 10.1016/j.cjca.2012.01.021.
Reference Type
BACKGROUND
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. No abstract available.
Reference Type
BACKGROUND
Sood MM, Larkina M, Thumma JR, Tentori F, Gillespie BW, Fukuhara S, Mendelssohn DC, Chan K, de Sequera P, Komenda P, Rigatto C, Robinson BM. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int. 2013 Sep;84(3):600-8. doi: 10.1038/ki.2013.170. Epub 2013 May 15.
Reference Type
BACKGROUND
Clase CM, Holden RM, Sood MM, Rigatto C, Moist LM, Thomson BK, Mann JF, Zimmerman DL. Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation? Nephrol Dial Transplant. 2012 Oct;27(10):3719-24. doi: 10.1093/ndt/gfs346.
Reference Type
BACKGROUND
Gebuis EP, Rosendaal FR, van Meegen E, van der Meer FJ. Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. Haematologica. 2011 Apr;96(4):583-9. doi: 10.3324/haematol.2010.035162. Epub 2010 Dec 29.
Reference Type
BACKGROUND
Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood. 2007 Mar 15;109(6):2419-23. doi: 10.1182/blood-2006-09-049262. Epub 2006 Nov 16.
Reference Type
BACKGROUND
Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, Bovill EG. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol. 2001 Mar;112(3):572-7. doi: 10.1046/j.1365-2141.2001.02635.x.
Reference Type
BACKGROUND
Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost. 2005 May;93(5):872-5. doi: 10.1160/TH04-12-0773.
Reference Type
BACKGROUND
Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e152S-e184S. doi: 10.1378/chest.11-2295.
Reference Type
BACKGROUND
Lam J, Schulman S, Witt DM, Vandvik PO, Qayyum F, Holbrook AM. Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy. 2013 Nov;33(11):1184-90. doi: 10.1002/phar.1302. Epub 2013 Jun 6.
Reference Type
BACKGROUND
Rombouts EK, Rosendaal FR, Van Der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost. 2007 Oct;5(10):2043-8. doi: 10.1111/j.1538-7836.2007.02715.x. Epub 2007 Jul 31.
Reference Type
BACKGROUND
Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012 Feb;59(2):186-95. doi: 10.1053/j.ajkd.2011.10.041. Epub 2011 Dec 9.
Reference Type
BACKGROUND
Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD. Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012 Sep;82(5):605-10. doi: 10.1038/ki.2012.191. Epub 2012 May 30.
Reference Type
BACKGROUND
Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant. 2014 Sep;29(9):1633-8. doi: 10.1093/ndt/gft459. Epub 2013 Nov 26.
Reference Type
BACKGROUND
Ford SK, Misita CP, Shilliday BB, Malone RM, Moore CG, Moll S. Prospective study of supplemental vitamin K therapy in patients on oral anticoagulants with unstable international normalized ratios. J Thromb Thrombolysis. 2007 Aug;24(1):23-7. doi: 10.1007/s11239-007-0014-z. Epub 2007 Feb 24.
Reference Type
BACKGROUND
Reese AM, Farnett LE, Lyons RM, Patel B, Morgan L, Bussey HI. Low-dose vitamin K to augment anticoagulation control. Pharmacotherapy. 2005 Dec;25(12):1746-51. doi: 10.1592/phco.2005.25.12.1746.
Reference Type
BACKGROUND
Majeed H, Rodger M, Forgie M, Carrier M, Taljaard M, Scarvelis D, Gonsalves C, Rodriguez RA, Wells PS. Effect of 200muG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial. Thromb Res. 2013 Sep;132(3):329-35. doi: 10.1016/j.thromres.2013.07.019. Epub 2013 Jul 29.
Reference Type
BACKGROUND
Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood. 2004 Nov 1;104(9):2682-9. doi: 10.1182/blood-2004-04-1525. Epub 2004 Jul 1.
Reference Type
BACKGROUND
Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010 Jan;8(1):202-4. doi: 10.1111/j.1538-7836.2009.03678.x. Epub 2009 Oct 30.
Reference Type
BACKGROUND
White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007 Feb 12;167(3):239-45. doi: 10.1001/archinte.167.3.239.
Reference Type
BACKGROUND
Juurlink DN. Drug interactions with warfarin: what clinicians need to know. CMAJ. 2007 Aug 14;177(4):369-71. doi: 10.1503/cmaj.070946. No abstract available.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-8200
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Vitamin K to Attenuate Coronary Artery Calcification in Hemodialysis Patients
NCT01528800
COMPLETED
PHASE2
Vitamin K2 Supplementation and Vascular Calcification
NCT04539418
COMPLETED
PHASE4
Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients
NCT02610933
COMPLETED
PHASE4
Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients
NCT01742273
TERMINATED
PHASE3
Role of Vitamin K2 in Chronic Kidney Disease
NCT05942053
RECRUITING
PHASE4
Comparative Study Evaluating the Effect of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients
NCT04477811
COMPLETED
PHASE2/PHASE3
Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)
NCT02517580
COMPLETED
PHASE2
Impact of Vitamin D Therapies on Chronic Kidney Disease
NCT01222234
COMPLETED
NA
Vitamin D and Cardiac Autonomic Tone in Hemodialysis
NCT01774812
COMPLETED
PHASE2
Vitamin D Replacement After Kidney Transplant
NCT00748618
COMPLETED
NA
Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D
NCT01312441
TERMINATED
PHASE4
Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients
NCT01407601
COMPLETED
PHASE3
Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients
NCT01173848
TERMINATED
PHASE3
Effect of Vitamin K 2 on Vascular Calcification in Hemodialysis Patients
NCT04145492
UNKNOWN
PHASE2/PHASE3
Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients
NCT01675206
COMPLETED
PHASE3
Pilot Study- Treat to Target Vitamin D in End Stage Renal Disease
NCT04167111
WITHDRAWN
NA
Hemodialysis Vitamin D Pilot
NCT01214928
COMPLETED
NA
Vitamin k1 and Its Relation to Vascular Calcification in Hemodialysis Patients
NCT05060809
COMPLETED
PHASE4
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
NCT00528788
COMPLETED
PHASE4
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease
NCT00781417
COMPLETED
NA
Vitamin D, Oxidative Stress and Inflammation in Hemodialysis
NCT05460338
COMPLETED
PHASE2/PHASE3
Effect of Vitamin D Supplementation on Balance in CKD
NCT03710161
TERMINATED
PHASE4
Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
NCT01384539
COMPLETED
PHASE3
Oxidative Stress and Hemodialysis Access Failure
NCT00410449
COMPLETED
Provision of Antioxidant Therapy in Hemodialysis (PATH) Study
NCT00237718
COMPLETED
PHASE2